Gustav Ullenhag
About
Gustav Ullenhag is a scholar working on Oncology, Immunology and Molecular Biology.
According to data from OpenAlex, Gustav Ullenhag has authored 97 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 68 papers in Oncology, 47 papers in Immunology and 26 papers in Molecular Biology. Recurrent topics in Gustav Ullenhag's work include Immunotherapy and Immune Responses (39 papers), CAR-T cell therapy research (31 papers) and Cancer Immunotherapy and Biomarkers (22 papers). Gustav Ullenhag is often cited by papers focused on Immunotherapy and Immune Responses (39 papers), CAR-T cell therapy research (31 papers) and Cancer Immunotherapy and Biomarkers (22 papers). Gustav Ullenhag collaborates with scholars based in Sweden, Denmark and United Kingdom. Gustav Ullenhag's co-authors include Angelica Loskog, Emma Eriksson, Jessica Wenthe, Sandra Irenaeus, Szilvia Mosolits, Håkan Mellstedt, Jan‐Erik Frödin, Roger Olofsson Bagge, Lars Ny and Anna Dimberg and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.
In The Last Decade
Gustav Ullenhag
90 papers receiving 1.8k citations
Peers
Gustav Ullenhag
Christina Coughlin United States
Natalia Aptsiauri Spain
Christoph Höeller Austria
Kalijn F. Bol Netherlands
Sebastian Ochsenreither Germany
Mark R. Albertini United States
Katie A. Matatall United States
An Song United States
Michael L. Salgaller United States
Renate S. Hagedoorn Netherlands
Citations per year, relative to Gustav Ullenhag Gustav Ullenhag (= 1×)
peers
Christina Coughlin
Countries citing papers authored by Gustav Ullenhag
Since
Specialization
Citations
This map shows the geographic impact of Gustav Ullenhag's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gustav Ullenhag with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gustav Ullenhag more than expected).
Fields of papers citing papers by Gustav Ullenhag
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Gustav Ullenhag. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gustav Ullenhag. The network helps show where Gustav Ullenhag may publish in the future.
Co-authorship network of co-authors of Gustav Ullenhag
This figure shows the co-authorship network connecting the top 25 collaborators of Gustav Ullenhag. A scholar is included among the top collaborators of Gustav Ullenhag based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gustav Ullenhag. Gustav Ullenhag is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Helgadóttir, Hafdís T., Roger Olofsson Bagge, Nils Elander, et al.. (2024). 1122P The role of imaging during follow-up after radical surgery of stage IIb-c and III cutaneous malignant melanoma: Survival results from an interim analysis of a randomized prospective multicenter study (TRIM). Annals of Oncology. 35. S739–S739.
2.
All‐Eriksson, Charlotta, Christian Cahlin, Nils Elander, et al.. (2024). Long-term overall survival after isolated liver perfusion with melphalan in patients with isolated liver metastases of uveal melanoma (SCANDIUM trial).. Journal of Clinical Oncology. 42(16_suppl). 9532–9532.
3.
Wenthe, Jessica, et al.. (2024). CD40 stimulation via CD40 ligand enhances adenovirus‐mediated tumour immunogenicity including ‘find‐me’, ‘eat‐me’, and ‘kill‐me’ signalling. Journal of Cellular and Molecular Medicine. 28(7). e18162–e18162.
4.
Helgadóttir, Hafdís T., et al.. (2024). 1079MO Survival before and after the introduction of adjuvant treatment in stage III melanoma: A nationwide registry-based study. Annals of Oncology. 35. S715–S716.
5.
Musher, Benjamin, Eric K. Rowinsky, Brandon G. Smaglo, et al.. (2024). LOAd703, an oncolytic virus-based immunostimulatory gene therapy, combined with chemotherapy for unresectable or metastatic pancreatic cancer (LOKON001): results from arm 1 of a non-randomised, single-centre, phase 1/2 study. The Lancet Oncology. 25(4). 488–500.
6.
Koliadi, Anthoula, et al.. (2024). Multiple immune-related adverse events secondary to checkpoint inhibitor therapy in patients with advanced cancer: association with treatment effectiveness. Frontiers in Oncology. 14. 1399171–1399171.
7.
Helgadóttir, Hildur, et al.. (2023). Survival after introduction of adjuvant treatment in stage III melanoma: a nationwide registry-based study. JNCI Journal of the National Cancer Institute. 115(9). 1077–1084.
8.
Bagge, Roger Olofsson, Charlotta All‐Eriksson, Christian Cahlin, et al.. (2023). Survival after isolated hepatic perfusion as a treatment for uveal melanoma liver metastases: Results from a randomized controlled trial (the SCANDIUM trial).. Journal of Clinical Oncology. 41(17_suppl). LBA9512–LBA9512.
9.
Koliadi, Anthoula, et al.. (2023). Predicting immune‐related adverse events using a simplified frailty score in cancer patients treated with checkpoint inhibitors: A retrospective cohort study. Cancer Medicine. 12(12). 13217–13224.
10.
Bagge, Roger Olofsson, Charlotta All‐Eriksson, Christian Cahlin, et al.. (2023). Isolated Hepatic Perfusion With Melphalan for Patients With Isolated Uveal Melanoma Liver Metastases: A Multicenter, Randomized, Open-Label, Phase III Trial (the SCANDIUM Trial). Journal of Clinical Oncology. 41(16). 3042–3050.
11.
Koliadi, Anthoula, et al.. (2023). The role of dacarbazine and temozolomide therapy after treatment with immune checkpoint inhibitors in malignant melanoma patients: A case series and meta‐analysis. Pigment Cell & Melanoma Research. 37(3). 352–362.
12.
Wenthe, Jessica, Rafael Moreno, Gustav Ullenhag, et al.. (2022). Immune priming using DC- and T cell-targeting gene therapy sensitizes both treated and distant B16 tumors to checkpoint inhibition. Molecular Therapy — Oncolytics. 24. 429–442.
13.
Helgadóttir, Hildur, Yvonne Brandberg, Johan Hansson, et al.. (2020). TRIM study protocol - a prospective randomized multicenter Trial to assess the Role of Imaging during follow-up after radical surgery of stage IIB-C and III cutaneous malignant Melanoma. BMC Cancer. 20(1). 1197–1197.
14.
Georganaki, Maria, et al.. (2020). Tumor endothelial ELTD1 as a predictive marker for treatment of renal cancer patients with sunitinib. BMC Cancer. 20(1). 339–339.
15.
Jespersen, Henrik, Roger Olofsson Bagge, Gustav Ullenhag, et al.. (2019). Concomitant use of pembrolizumab and entinostat in adult patients with metastatic uveal melanoma (PEMDAC study): protocol for a multicenter phase II open label study. BMC Cancer. 19(1). 415–415.
16.
Eriksson, Emma, Jessica Wenthe, Gustav Ullenhag, et al.. (2017). Shaping the Tumor Stroma and Sparking Immune Activation by CD40 and 4-1BB Signaling Induced by an Armed Oncolytic Virus. Clinical Cancer Research. 23(19). 5846–5857.
17.
Wenthe, Jessica, Sara M. Mangsbo, Emma Eriksson, et al.. (2017). Adenovirus-mediated CD40L gene transfer increases Teffector/Tregulatory cell ratio and upregulates death receptors in metastatic melanoma patients. Journal of Translational Medicine. 15(1). 79–79.
18.
Lyth, Johan, Hanna Eriksson, Johan Hansson, et al.. (2014). Trends in cutaneous malignant melanoma in Sweden 1997-2011: thinner tumours and improved survival among men. British Journal of Dermatology. 172(3). 700–706.
19.
Bagge, Roger Olofsson, Lars Ny, Malin Sternby Eilard, et al.. (2014). Isolated hepatic perfusion as a treatment for uveal melanoma liver metastases (the SCANDIUM trial): study protocol for a randomized controlled trial. Trials. 15(1). 317–317.
20.
Plym, Anna, et al.. (2013). Clinical characteristics, management and survival in young adults diagnosed with malignant melanoma: A population-based cohort study. Acta Oncologica. 53(5). 688–696.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Christina Coughlin Breakdown of academic impact, for papers by Natalia Aptsiauri Breakdown of academic impact, for papers by Christoph Höeller Breakdown of academic impact, for papers by Kalijn F. Bol Breakdown of academic impact, for papers by Sebastian Ochsenreither Breakdown of academic impact, for papers by Mark R. Albertini Breakdown of academic impact, for papers by Katie A. Matatall Breakdown of academic impact, for papers by An Song Breakdown of academic impact, for papers by Michael L. Salgaller Breakdown of academic impact, for papers by Renate S. Hagedoorn